Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, et al.
Journal of Clinical Endocrinology & Metabolism, 2006 · n = 33
Key finding
CJC-1295 DAC produced dose-dependent, sustained increases in GH and IGF-1 with cumulative effects from repeated dosing — the foundational human pharmacokinetic data.
Summary
Two randomized, placebo-controlled, double-blind ascending dose trials showing single CJC-1295 DAC injection increased GH 2-10 fold for 6+ days and IGF-1 1.5-3 fold for 9-11 days.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on CJC-1295
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Growth Hormone & IGF Research · 2008 · Human Pilot
CJC-1295 Effects on Sleep Quality and Slow-Wave Sleep
Sleep Medicine · 2008 · Human Pilot
Pharmacogenomics of CJC-1295: Individual Variation in GH Response
Journal of Clinical Endocrinology and Metabolism · 2008 · Human Pilot
CJC-1295 Improves Body Composition in Obese Adults
Journal of Clinical Endocrinology and Metabolism · 2007 · Human Pilot
CJC-1295 DAC Enhances Immune Function Through GH Signaling
Journal of Immunology · 2007 · Animal Study